Significant biosimilar activities this week include:

  • 28 Sep 20: Innovent announced its ph III trial of Byvasda® (proposed bevacizumab biosimilar) in combination with Tyvyt® (sintilimab) met its primary endpoints of progression-free survival and overall survival.  In...

01 Oct 20 | AU | Lupin | Lupin receives approval for biosimilar etanercept in Australia under the trade names Etera® and Rymti® in PFS presentations.

15 Sep 20 | CA | Merck | Merck announced Health Canada has approved Brenzys® (biosimilar etanercept) for four new indica...

Significant biosimilar activities this week include:

  • 24 Aug 20, JP: Merck announced Keytruda® (pembrolizumab) has received two additional approvals from the Japanese Pharmaceuticals and Medical Devices Agency:

    • new indication for the treatment of patient...

Significant biosimilar activities this week include:

  • May 29: in a filing to the Securities and Exchange Commission, Alexion announced it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to m...

Significant biosimilar activities this week include:

  • At the beginning of March 2020, the UK High Court ruled filing errors in a Supplementary Protection Certificate (SPC) for Lucentis® (ranibizumab) have cut almost two years from Roche/Genentech's protection in the...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags